ArticleGynecologic oncology2026
Atezolizumab in combination with neoadjuvant chemotherapy and interval cytoreductive surgery for patients with newly diagnosed advanced-stage epithelial ovarian cancer: the AdORN study.
Article in Gynecologic oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Development of diffuse cutaneous squamous cell carcinoma in situ after chemotherapy for ovarian carcinoma and remission with PD1-inhibitor.Gynecologic oncology reports · 2024Article
- Review
- Neoadjuvant treatment in ovarian cancer: New perspectives, new challenges.Frontiers in oncology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
Abstract
objectiveEvaluate safety, efficacy, and response markers to atezolizumab, an immune checkpoint inhibitor, when combined with neoadjuvant chemotherapy (NACT) for primary epithelial ovarian, tubal, and peritoneal cancer (EOC).
methodsEligible patients had high-grade stage III/IV EOC planned for NACT and interval cytoreductive surgery (ICS). After pretreatment biopsy, patients receivedweekly paclitaxel (80 mg/m2) with carboplatin (AUC6) and atezolizumab (1200mg) every 3 weeks for 3 cycles before ICS, and 3 cycles +/- bevacizumab post-ICS, followed by maintenance atezolizumab +/- bevacizumab or a PARPinhibitor. The primary endpoint was frequency of delay in ICS due to atezolizumab-related toxicities. Frequency/severity of adverse events (AE), response prior to ICS, and immune translational parameters were assessed.
resultsNegative results of IMagyn050 led to early termination; 18 of 40 planned patients enrolled: median age 69 years (range 46-87); majority were white (78%), had Stage III disease (72%), high-grade serous histology (100%), and no BRCAmutation (72%). Fifteen patients underwent ICS; 3 stopped protocol therapy prior to cycle 3 for non-atezolizumab-related reasons. Thromboembolism led to delay of ICS in one patient. Optimal cytoreduction was achieved in 13 (86%) patients. Treatment-related AEs were as expected. Partial response occurred in 9 (60%) and stable disease in 6 (40%). Patients with response versus stable disease had elevated post-treatment CXCL10, TNFα, and IL10. Immune compartments showed increased inflammatory markers, while tumor showed increased inflammatory and suppressive markers.
conclusionsNACT with atezolizumab was feasible and did not delay ICS. Translational parameters showed heterogeneous changes reflecting both immune activation and adaptive immune resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.